Wall Street analysts forecast that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) will report sales of $221.51 million for the current fiscal quarter, Zacks reports. Seven analysts have issued estimates for Alnylam Pharmaceuticals’ earnings, with estimates ranging from $211.20 million to $225.85 million. Alnylam Pharmaceuticals reported sales of $125.85 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 76%. The company is expected to issue its next earnings results on Thursday, November 4th.
According to Zacks, analysts expect that Alnylam Pharmaceuticals will report full year sales of $861.11 million for the current fiscal year, with estimates ranging from $841.07 million to $881.34 million. For the next year, analysts expect that the business will report sales of $1.27 billion, with estimates ranging from $1.10 billion to $1.50 billion. Zacks’ sales calculations are a mean average based on a survey of research analysts that follow Alnylam Pharmaceuticals.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Monday, August 2nd. The biopharmaceutical company reported ($1.61) earnings per share for the quarter, meeting the consensus estimate of ($1.61). The firm had revenue of $220.55 million during the quarter, compared to analyst estimates of $193.66 million. Alnylam Pharmaceuticals had a negative net margin of 128.96% and a negative return on equity of 88.43%. The business’s quarterly revenue was up 112.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.67) EPS.
NASDAQ ALNY traded up $2.18 on Tuesday, hitting $187.97. The company had a trading volume of 401,741 shares, compared to its average volume of 636,962. The company has a market capitalization of $22.34 billion, a PE ratio of -24.77 and a beta of 1.22. The company’s fifty day moving average price is $189.16 and its 200-day moving average price is $161.23. The company has a debt-to-equity ratio of 0.51, a current ratio of 4.91 and a quick ratio of 4.76. Alnylam Pharmaceuticals has a 12-month low of $119.29 and a 12-month high of $209.73.
In other news, insider Akshay Vaishnaw sold 14,708 shares of the business’s stock in a transaction dated Friday, June 18th. The shares were sold at an average price of $175.00, for a total transaction of $2,573,900.00. Following the transaction, the insider now owns 24,953 shares of the company’s stock, valued at approximately $4,366,775. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Laurie Keating sold 6,812 shares of the company’s stock in a transaction dated Monday, July 12th. The shares were sold at an average price of $178.96, for a total transaction of $1,219,075.52. Following the completion of the transaction, the executive vice president now directly owns 6,944 shares in the company, valued at approximately $1,242,698.24. The disclosure for this sale can be found here. In the last three months, insiders have sold 118,563 shares of company stock worth $23,030,536. Corporate insiders own 2.30% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Parametric Portfolio Associates LLC lifted its position in Alnylam Pharmaceuticals by 9.8% in the second quarter. Parametric Portfolio Associates LLC now owns 198,685 shares of the biopharmaceutical company’s stock valued at $33,681,000 after buying an additional 17,743 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG increased its stake in Alnylam Pharmaceuticals by 31.7% during the second quarter. B. Metzler seel. Sohn & Co. Holding AG now owns 1,945 shares of the biopharmaceutical company’s stock worth $330,000 after purchasing an additional 468 shares during the period. Y Intercept Hong Kong Ltd increased its stake in Alnylam Pharmaceuticals by 101.9% during the second quarter. Y Intercept Hong Kong Ltd now owns 7,592 shares of the biopharmaceutical company’s stock worth $1,287,000 after purchasing an additional 3,832 shares during the period. Marshall Wace North America L.P. purchased a new stake in Alnylam Pharmaceuticals during the second quarter worth about $18,407,000. Finally, Morgan Stanley increased its stake in Alnylam Pharmaceuticals by 5.4% during the second quarter. Morgan Stanley now owns 1,882,651 shares of the biopharmaceutical company’s stock worth $319,147,000 after purchasing an additional 96,697 shares during the period. 93.34% of the stock is currently owned by institutional investors.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. The firm’s products include ONPATTRO, GIVLAARI, and OXLUMO. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases.
Read More: What is the Gross Domestic Product (GDP)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.